HPV vaccination before pregnancy tied to fewer preterm births

The human papillomavirus vaccine has spent its whole public life being justified on the same grounds: it prevents cancer. A large nationwide study published in The BMJ on 7 October now makes a quieter, wider claim, suggesting that the protection it offers may reach into pregnancy itself. Drawing on Swedish registers covering more than six hundred thousand first births, the researchers found that women vaccinated against HPV before conception had modestly but consistently lower odds of a string of complications, above all preterm birth.

The numbers are the point. The cohort follows 624,713 singleton births to first-time mothers aged 16 to 35 in Sweden between 2006 and 2023; about 14.8 per cent had received at least one dose of the quadrivalent vaccine before pregnancy. After adjusting for confounders, vaccination was associated with lower odds of every outcome the team examined. The clearest effects were on preterm birth before 37 weeks, with an adjusted odds ratio of 0.95, and on very preterm birth between 28 and 31 weeks, at 0.85. Spontaneous preterm birth, the early rupture of membranes and a baby that was small for its gestational age all tracked in the same protective direction. The reduction was generally larger among women vaccinated at younger ages.

The design matters as much as the result. This is a matched case-control study built on linked national registers, which removes a lot of the noise that has dogged earlier work. The obvious worry is confounding: vaccinated and unvaccinated women may differ in wealth, health behaviour and access to care, and those differences, not the vaccine, could explain better pregnancy outcomes. The authors lean on register data and careful matching to blunt that objection, and the direction of the effect, with the strongest signal on the most premature births, is biologically plausible. HPV infection and the treatment of cervical lesions are already known to raise the risk of adverse pregnancy outcomes, so a vaccine that prevents that inflammation might reasonably be expected to take some risk away.

The size of the effect deserves a steady reading. These are relative odds, and a ratio of 0.95 on preterm birth, while real and statistically clear, is a modest reduction on its own. The news is not that HPV vaccination is a magic shield for pregnancy. It is that a vaccine already recommended for cancer prevention appears to carry an extra, free benefit for the pregnancies that follow it. For public health, that is the kind of argument that actually changes behaviour, because it hands the vaccine a second, easier reason to be taken.

That matters because HPV vaccination rates, even in well-off countries, still leave large gaps, and the people who could gain the most are often the hardest to reach. A benefit that shows up a decade later, in a healthy first pregnancy, lands at a moment when young women and their families are already paying attention. The authors themselves frame it cautiously: the findings extend the case for vaccination beyond cancer prevention, but they do not replace that case, and the study does not prove that vaccination causes the reduction.

Preterm birth remains a leading global cause of infant death and long-term illness, and anything that nudges it down at population scale is worth taking seriously. Whether this association holds up as more data accumulate, the Swedish registers have done what good epidemiology does: turned a faint, plausible signal into something a guideline can eventually be built on.